Bluebird bio, Inc.
BLUE
Classement en actions
#15674
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Prix de l'action
$4.97
Dernière synchronisation: 2025-06-02
Capitalisation boursière
$318.62M
Changement (1 jour)
0.00%
Changement (1 an)
-38.03%
Pays
US
Échange Bluebird bio, Inc. (BLUE)
Catégorie
Healthcare
Capitalisation boursière de Bluebird bio, Inc.(BLUE)
Capitalisation boursière: $318.62M
En October 2026, Bluebird bio, Inc. a une capitalisation boursière de $318.62M. Cela fait de Bluebird bio, Inc. la 15674th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Bluebird bio, Inc. du 2018 au 2026
BLUE par rapport au top 5 des plus populaires stocks
